Journal News

Pesticide disrupts neuronal potentiation

Ecem Arpaci
By Ecem Arpaci
June 17, 2025

The pesticide deltamethrin is widely considered a safer alternative to other chemicals, such as organophosphates due to being less toxic to mammals. However, previous studies in mice showed that deltamethrin exposure at early stages of development can lead to neuronal toxicity, but scientists do not understand the mechanism involved. Therefore, Leandra Koff and a team led by Fernanda Laezza from the Sealy Center of Environmental Health & Medicine at the University of Texas Medical Branch and colleagues in the U.S. investigated how deltamethrin induces neuronal toxicity and published their results in Molecular & Cellular Proteomics.

juliendn via Flickr

The team focused on brain-derived extracellular vesicles, or BDEVs, structures that transport molecules, such as signaling proteins, between cells in the brain. Because changes in the BDEV proteome can be a sign of disease, the team used a mass spectrometry–based approach to compare the protein content of BDEVs in mice exposed to deltamethrin and controls. They found several differentially expressed proteins between the two groups. Some alterations are associated with neuronal structure, transport and long-term potentiation, which promotes synaptic connections and plays a role in learning and memory. These proteomic differences could be one explanation for neuronal toxicity due to impaired nutrient transport and growth.

BDEV protein levels could be used as biomarkers to evaluate the risk of neurodevelopmental disorders. More research is needed to understand how these proteins disrupt neuronal function at later stages of development.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ecem Arpaci
Ecem Arpaci

Ecem Arpaci is a biochemistry student at Imperial College London and a research intern at Radboud University Medical Center. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Spider-like proteins spin defenses to control immunity
News

Spider-like proteins spin defenses to control immunity

Oct. 17, 2025

Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.

AI-designed biomarker improves malaria diagnostics
Journal News

AI-designed biomarker improves malaria diagnostics

Oct. 8, 2025

Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.

Matrix metalloproteinase inhibitor reduces cancer invasion
Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Oct. 8, 2025

Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.